Atezolizumab plus bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab are systemic therapies that have been approved for the treatment of HCC; a combination of atezolizumab (anti-PDL1 antibody) and bevacizumab (anti-VEGF antibody) was approved for advanced-stage HCC cases as first-line therapies, but if the patient has contraindications to these drugs, sorafenib and lenvatinib can be used. The gene discussed is CD274; the disease is hepatocellular carcinoma.